ICG Fluorescence Imaging for Tumor Margin Assessment in Breast-Conserving Surgery
ICG fluorescence imaging can be used as a supplementary intraoperative tool for margin assessment during breast-conserving surgery, but it should not replace standard pathological evaluation methods such as frozen section analysis. The technology shows promise in reducing re-excision rates but lacks sufficient evidence to serve as a standalone margin assessment technique.
Current Evidence and Performance
The most recent clinical data from 2024 demonstrates that ICG-assisted breast-conserving surgery achieved negative margins in 88% of cases versus 65% with standard methods (p < 0.001) and significantly reduced re-excision rates from 22% to 8% (p = 0.002) 1. This represents a meaningful clinical improvement in immediate surgical outcomes.
However, the diagnostic accuracy shows important limitations:
- Sensitivity: 81.82% (comparable to frozen section)
- Specificity: 75.82% (lower than frozen section's 94.83%) 2
The relatively poor specificity means ICG fluorescence produces false-positive signals, potentially leading to unnecessary tissue removal if used without pathological confirmation.
Optimal Dosing Protocol
Based on available evidence, the 1.0 mg/kg intravenous dose administered 2 hours preoperatively provides superior sensitivity (87.5%) compared to the 0.5 mg/kg dose (66.67%), though at the cost of reduced specificity (74.42% vs 93.33%) 2. The higher dose appears more clinically useful for detecting residual tumor, accepting some false-positive signals that can be clarified by pathology.
Technical Considerations
ICG accumulates reliably in breast cancer tissue with:
- Average tumor fluorescence intensity: 219.41 ± 32.81 arbitrary units
- Signal-to-background ratio: 2.14 ± 0.60 for tumor versus normal tissue 3
The dye remains stable in tissue even after formalin fixation, allowing correlation with final pathology 4.
Clinical Integration Strategy
Use ICG fluorescence as an adjunct to—not replacement for—standard margin assessment:
- Administer 1.0 mg/kg ICG intravenously 2 hours before surgery for optimal tumor visualization
- Use NIR imaging intraoperatively to guide initial resection and identify suspicious areas in the surgical bed
- Send all specimens for standard frozen section or touch prep analysis as the definitive margin assessment
- Consider additional excision of fluorescent areas only when confirmed by pathological evaluation
Important Caveats
Limitations of Current Evidence
- No established guidelines from major surgical oncology societies (SSO, ASTRO) specifically address ICG for margin assessment 5, 6
- The FDA-approved indications for ICG focus on hepatic function studies and ophthalmic angiography, not tumor margin detection 7
- Long-term oncological outcomes (local recurrence rates) remain similar between ICG-guided and standard techniques 1
Practical Pitfalls
- False positives occur frequently due to ICG accumulation in inflammatory tissue, benign lesions, and areas of increased vascularity 2
- Heparin preparations containing sodium bisulfite interfere with ICG absorption and should be avoided 7
- The dye must be used within 6 hours of reconstitution 7
- Standardization of imaging systems, dosing protocols, and interpretation criteria remains incomplete across institutions 8, 9
Context Within Margin Guidelines
The established standard for breast-conserving surgery margins is "no ink on tumor" for invasive breast cancer 5, 6. This guideline was developed to reduce unnecessary re-excisions while maintaining oncological safety. ICG fluorescence imaging should be viewed as a technology to help achieve this standard more efficiently in the initial operation, not to redefine what constitutes an adequate margin.
The primary value of ICG lies in reducing the 20-30% re-excision rate that persists even with the "no ink on tumor" standard 6, by providing real-time intraoperative feedback that can prompt immediate additional excision when pathology confirms positive margins.